Phase II Study of a Comprehensive Treatment Using Perioperative Chemotherapy Combined with Cytoreductive Surgery for Curatively Resected Gastric Cancer Patients with Positive Peritoneal Wash Cytology (gjghv2n3a5) - synergy - synergy

Phase II Study of a Comprehensive Treatment Using Perioperative Chemotherapy Combined with Cytoreductive Surgery for Curatively Resected Gastric Cancer Patients with Positive Peritoneal Wash Cytology

Pages 108-113

1NPO Organization to Support Peritoneal Surface Malignancy Treatment; 2Regional Caner Therapies, Peritoneal Dissemination Center, Kishiwada Tokushukai Hospital, Kishiwada, Oosaka, Japan; 3Regional Caner Therapies, Peritoneal Dissemination Center, Department of Surgery, Kusatsu General Hospital, Minami-Kusatsu, Shiga, Japan; 4Department of Oncology, Zhongnam Hospital, Cancer Center of Wuhan University Wuhan, China; 5Department of Hospital Pharmacy, School of Medicine, Kanazawa University; 6Ikeda Hospital, Shizuoka, Japan; 7Department of Molecular Targetting, Cancer Research Center, Kanazawa University, Kanazawa, Japan

http://dx.doi.org/10.12970/2308-6483.2014.02.03.5

Download PDF

Abstract: Patients with curatively resected gastric cancer patients with positive peritoneal wash cytology are called P0/Cy1 status. The aim of the present study is to verify the survival benefit of the comprehensive treatment for patients with P0/Cy1 status.

Twenty gastric cancer patients were diagnosed as P0/Cy1 by laparoscopy or laparotomy, and were treated with a comprehensive treatment consisting of neoadjuvant intraperitoneal/systemic chemotherapy (NIPS), cytoreductive surgery (CRS) consisting of gastrectomy with lymph node dissection and peritonectomy, intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) and postoperative systemic chemotherapy. At the second look laparotomy, the peritoneal wash cytology became negative in 15 patients. No grade 3, 4, 5 complications were experienced after second look operations for CRS. Median follow-up time is 3.7 years. Eight patients died of recurrence, but the other 21 patients are alive without recurrence. Five-year survival rate was 42%.

The present study demonstrated the efficacy and safety of the comprehensive treatment on the gastric cancer patients in P0/Cy1 status.

Keywords: Peritoneal metastasis, gastric cancer, peritoneal cytology, peritoneal wash cytology. Read more

  • Why Choose Synergy

    Synergy Publishers opens a portal to researchers and scholarly communities We aspire to be one of the best publishers for professional and scholarly societies. We maintain a balanced, independent editorial policy being fully committed to authors with honesty. We strive to proceed in a manner that is conducive to a sustainable future.